Tempus and Pathos agree to provide up to 500 thousand de-identified medical records on Alzheimer’s disease
Tempus and Pathos agree to provide up to 500 thousand de-identified medical records on Alzheimer’s disease
On October 23, Pathos, Tempus and pharmaceutical company Bristol Myers Squibb announced related agreements signed the previous day. The five-year agreement provides for Tempus to deliver up to 500 thousand de-identified medical records on Alzheimer’s disease and other specified neurological conditions to Pathos, along with a license to use them. Bristol Myers Squibb will receive rights to use the data and the Tempus Agent software to analyze them for drug development.
The Tempus regulatory filing in the United States specifies a target of up to 100 thousand records per year. Pathos describes the planned dataset as longitudinal, meaning it can show how patients’ conditions change over time. The agreement caps delivery at 500 thousand records over five years.
Payment depends on the number of records actually delivered: Pathos will pay 100 dollars per record, up to a total of 50 million dollars. The agreement also provides for up to 5 million dollars for the option to receive updates to the records.
Tempus is also licensing Tempus Agent, software for querying and analyzing the licensed records. Pathos will be able to use the data and software internally and to support Bristol Myers Squibb in developing therapeutic products. The Pathos announcement describes Foundry, the company’s proprietary AI system, as a tool for analyzing the dataset, testing hypotheses about disease biology and designing adaptive clinical trials, in which trial rules can change in response to interim data.
An additional agreement gives Bristol Myers Squibb rights to use the records and Tempus Agent. For each record delivered, Tempus will restrict further licensing to other companies for 18 months, with exceptions for Bristol Myers Squibb, Pathos and certain contractors. This period begins on the later of two dates: the record’s delivery date or October 22, 2027. Separately, Pathos states that Bristol Myers Squibb will have three years of exclusivity for Foundry-based support of neuroscience programs.